Clinical Trials Logo

Clinical Trial Summary

In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.


Clinical Trial Description

Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies. In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05423665
Study type Observational
Source University Hospital, Ghent
Contact Eline Meireson
Phone 0032 9 332 78 17
Email eline.meireson@uzgent.be
Status Recruiting
Phase
Start date June 22, 2023
Completion date February 1, 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Recruiting NCT05601375 - Speckle Tracking Echocardiography in Infants, Prenatally and Postnatally
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Completed NCT05059093 - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Completed NCT03067298 - Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
Recruiting NCT01981824 - Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study N/A
Recruiting NCT04215107 - Fetal Distribution of Feto-placental Blood Flow Related to Placental Nutrient Transport and Maternal Food Intake N/A
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Terminated NCT04084990 - Sleep Apnea and Fetal Growth Restriction Phase 3
Recruiting NCT04051567 - Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies Phase 4
Recruiting NCT04394611 - Metals and in Fetal Growth Restriction
Completed NCT01369940 - The NICHD Fetal Growth Study: Twin Gestations N/A
Not yet recruiting NCT03121196 - Social Deprivation and Pregnancy N/A
Recruiting NCT03177824 - Sildenafil Citrate for Treatment of Growth-restricted Fetuses Phase 3
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Completed NCT02379494 - First Trimester Prediction of Preeclampsia and Fetal Growth Restriction N/A
Completed NCT03046355 - Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women N/A
Not yet recruiting NCT05674487 - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) N/A
Not yet recruiting NCT05848869 - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction N/A
Recruiting NCT04438668 - Evaluation of the Safety and Performance of Centaflow N/A